ZM023

ZM023 is a preclinical-stage natural killer (NK) cell therapeutic being developed by Zumutor Biologics. It is designed to target a specific NK cell receptor, identified in company pipeline diagrams as the TLA NK cell receptor, to modulate innate immune responses against tumors. The primary focus of its development is for the treatment of breast cancer, with potential applications in other undisclosed oncology indications. As an NK cell therapy, ZM023 likely involves the activation or recruitment of NK cells to enhance their cytotoxic activity against malignant cells, leveraging the innate immune system's ability to identify and eliminate tumor cells.